Guggenheim Starts Aclaris Therapeutis (ACRS) at Buy
Tweet
Share
E-mailGet Alerts ACRS Hot Sheet
Price: $6.16 -0.48%
Rating Summary:
14 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 19
Rating Summary:
14 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 19
Join SI Premium – FREE
Guggenheim analyst Seamus Fernandez initiates coverage on Aclaris Therapeutis (NASDAQ: ACRS) with a Buy rating and a price target of $12.00.
For an analyst ratings summary and ratings history on Aclaris Therapeutis click here. For more ratings news on Aclaris Therapeutis click here.
Shares of Aclaris Therapeutis closed at $4.41 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Starts Rhythm Pharmaceuticals (RYTM) at Hold
- McEwen Copper closes $240M loan to fund Los Azules copper project
- Northrop Grumman wins $71.9M Air Force contract modification
Create E-mail Alert Related Categories
New CoverageRelated Entities
Maynard Um, Guggenheim, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
